The interim Phase I trial data was only from 35 people, but results look good so far.
An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a positive start in an early clinical trial.
Researchers running a Phase I safety trial for the drug, dubbed VERVE-102, publis... [5341 chars]